Trial Profile

A phase I study of KT-474

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 04 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KT 485 (Primary)
Indications Asthma; Atopic dermatitis; Hidradenitis suppurativa; Inflammatory bowel diseases; Rheumatoid arthritis
Focus Therapeutic Use

Most Recent Events

04 Jul 2025 New trial record
25 Jun 2025 Acording to Kymera Therapeutics media release, the company announced that in collaboration with Sanofi they will advance company's candidate KT-485 into the clinic.
25 Jun 2025 Acording to Kymera Therapeutics media release, the company expected to advance KT-485 into Phase 1 testing next year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com